about
Increased fracture risk in plasma cell dyscrasias is associated with poorer overall survival.Guidelines for the use of imaging in the management of patients with myeloma.A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.A rare complication of bone marrow aspiration and trephine biopsy: Staphylococcus aureus osteomyelitis and septicaemiaThe impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trialCorrespondence on: A rare complication of bone marrow aspiration and trephine biopsy: Staphylococcus aureus osteomyelitis and septicaemia - response to Eades & BapatReal-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with Multiple Myeloma receiving systemic anti-cancer therapyProphylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT
P50
Q38707697-13FC9239-CF6F-4AF8-A3EC-2DB0CF091443Q47329918-A3C4BD1D-F634-47CB-A23A-E4F0F5ED0C7EQ48232258-16FA9D65-AADF-430D-91AD-206327435788Q58576967-199D40EF-1D4A-4591-9792-E4BD73724367Q64258442-6D440C72-86CE-486B-92DD-DF6B712119CCQ90293244-56039913-8535-452D-B4EE-E3FEBFB9A704Q95636593-B192F5CA-1EA4-4398-B87E-4D03DCA2960BQ95818969-CA7D6520-6938-413D-9A16-B525C1BA987A
P50
description
researcher
@en
name
Guy Pratt
@en
type
label
Guy Pratt
@en
prefLabel
Guy Pratt
@en
P31
P496
0000-0002-6937-2852